AIM
REGN icon

Acrospire Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Acrospire Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$49K – 1119
2017
Q2 		$49K Hold
100
– – 0.05% 881
2017
Q1 		$39K Buy
+100
New +$37.1K 0.03% 1155
2016
Q4 		– Sell
-200
Closed -$80K – 2386
2016
Q3 		$80K Hold
200
– – 0.05% 723
2016
Q2 		$70K Buy
200
+100
+100% +$38.5K 0.05% 792
2016
Q1 		$36K Buy
+100
New +$41.2K 0.02% 1207

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Acrospire Investment Management's REGN Position: Q3 2017 in Review

Acrospire Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 100 shares — an estimated $49K sold.

Acrospire Investment Management first reported a position in REGN in Q1 2016 and held it in 5 quarters. The position peaked at $80K in Q3 2016. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • Acrospire Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 100 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $49K.
  • Acrospire Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Regeneron Pharmaceuticals position peaked at $80K in Q3 2016.
  • 605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.